Moscow-Based Companies Showcase Their Innovations at the Second International “Bioprom-2025” Forum

More than 300 companies in Moscow manufacture pharmaceuticals, medical devices, and equipment. From January to August 2025, local industrial enterprises increased the output of pharmaceuticals and medical-use materials by 4.4 percent compared to the same period in 2024. The figures were announced by Anatoly Garbuzov, Minister of the Moscow Government and Head of the Department of Investment and Industrial Policy.

“On behalf of Mayor Sergey Sobyanin, the development of the pharmaceutical and medical industries is one of the key priorities of the city’s strategy through 2030. Moscow provides comprehensive support to manufacturers, offering a wide range of effective tools. Companies continue to expand their production capacities, develop new medicines and devices, and broaden the portfolio of socially important products. As a result, in the first eight months of 2025, the output of medical-purpose pharmaceuticals and materials increased by 4.4 percent year-over-year,” said Anatoly Garbuzov.

As part of efforts to strengthen the industrial community and support sector development, Moscow-based companies actively participate in business initiatives. At the Second International Forum “Bioprom-2025: Industry and Technology for People,” leading pharmaceutical manufacturers and producers of bionic prosthetics presented their latest developments.

Generium-Next showcased five medicines manufactured within the Technopolis Moscow Special Economic Zone, including Russian bioanalogs of eculizumab, dornase alfa, imiglucerase, omalizumab, and alteplase. These genetically engineered drugs are used to treat rare and socially significant diseases. The company’s production capacity is sufficient to fully meet the needs of patients in Russia.

The company’s representatives emphasized that participation in the forum provides an important platform for cooperation with partners, presenting achievements, discussing industry prospects with policymakers, and exchanging expertise with professional peers.

Velfarm Group presented samples of its own active pharmaceutical ingredients synthesized using in-house facilities to ensure full-cycle localization of medicines.

According to Lyudmila Shcherbakova, President of Pharmaceutical Production, overcoming dependency on imported substances is a key challenge that the company addresses through its scientific and industrial capabilities. The synthesis technology has already been implemented for more than 40 molecules.

The company continues to invest in the development of new dosage forms and the production of the first Russian-made generic drugs. Speaking at a session on strategically important medicines, Grigory Levitsky, Head of Government and Public Relations, underscored the importance of a traceability system that confirms domestic production of pharmaceutical substances.

The forum also featured cyber hand prostheses and foot modules developed by Motorica, a resident of the Technopolis Moscow SEZ and the Skolkovo Innovation Center. During the panel discussion “Where to Find Funding for Bioeconomy: From Research to IPO?”, CEO Andrey Davidyuk discussed investment strategies to maintain technological leadership and the challenges of entering public markets